The Centers for Disease Control and Prevention yesterday issued a health advisory warning of an uptick over the last year in meningococcal disease in which isolates show the gene associated with penicillin resistance and mutations associated with ciprofloxacin resistance.

CDC said the majority of cases were in Hispanic individuals.

The agency recommends the following for providers and clinicians:

  • Health care providers should perform antimicrobial susceptibility testing to determine susceptibility of all meningococcal isolates to penicillin before changing from empirical treatment with cefotaxime or ceftriaxone to penicillin or ampicillin.
  • In states that have experienced meningococcal disease cases caused by ciprofloxacin-resistant strains within the past 1–2 years, clinicians and public health staff should consider AST on meningococcal isolates to inform prophylaxis decisions. AST should not delay the initiation of prophylaxis with ciprofloxacin, rifampin or ceftriaxone.

Related News Articles

Blog
As hospitals and health systems look for sustainable and scalable solutions to help address rising behavioral health needs across the country, digital tools…
Headline
The Centers for Medicare & Medicaid Services Dec. 15 published the Measures Under Consideration List for 2025. These are measures that CMS is considering…
Blog
The holiday season is often depicted as a time of joy and celebration, but for health care professionals it can also be a busy and emotionally demanding time…
Headline
The Centers for Medicare & Medicaid Services Dec. 11 announced the launch of the Make America Healthy Again: Enhancing Lifestyle and Evaluating Value-based…
Headline
The Advisory Committee on Immunization Practices Dec. 5 recommended individual-based decision-making for parents deciding whether to give the hepatitis B…
Headline
Nirsevimab was found to be 80% effective at preventing respiratory syncytial virus-associated intensive care unit admissions during the 2024-2025 RSV season,…